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INTRODUCTION
Few clinical studies have found that dietary or nutritional factors significantly
influence ulcerative colitis (UC}(l,2}. It is noteworthy, however, that a range of factors
have been researched including dietary components such as refined sugars (3,4},
allergenic foods (1,5,6} and fast foods (7), as well as nutritional supplement effects from
fish oil (2), zinc (8), glutamine (9), folate (10, 11} and alpha-tocopherolquinone (12}.
More recently investigators have also examined the interelationships between bowel
flora and UC, including factors such as flora changes (13,14), endotoxemia (15} and
supplementation effects with Lactobacillous species (16,17).
These studies taken together and a recent review of UC (18) suggest that nutritional influences on UC may likely be multifactorial. We therefore report the findings of
a retrospective chart review study of 24 consecutive UC patients who presented to an
outpatient medical office in which treatment emphasized a comprehensive nutritional
regimen, including a sugar-free hypoallergenic diet and nutritional supplementation.

METHODS
Subjects were included in this study who presented for treatment of ulcerative
colitis to an outpatient medical practice between March 10, 1992 and January 20,
1995. All subjects had at least two follow-up appointments to monitor compliance with
dietary and nutritional supplementation recommendations, and to assess disease status
through reported symptoms and medication dosage changes. Exclusion criteria were:
inadequate follow-up visits (nine}; advanced age (> 70 years old - seven); other major
illnesses (three); non-compliance (two}; and medical complications during treatment (two}.
Twenty-four subjects (15 male, 9 female) were enrolled in this study. Subject
ages at presentation ranged from 15 to 67 years old (average= 41.3 years}. Although
all subjects were seeking UC treatment, 14 (58.3 %} specifically reported having
colonoscopic and/or sigmoidoscopic tests done by previous physicians to confirm their
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diagnosis. At presentation, 17 subjects were on one or more medications - 8 on
sulfasalazine (dose range of 1000 - 5000 mg per day); 7 on prednisone (dose range of
2.5 to 25 mg per day); 5 on olsalazine/dipentum (dose range 500 - 2000 mg per day);
3 on mesalnine/asacol (dose range 600 - 2400 mg per day}; 1 on immuran (50 mg per
day); 1 on cyclosporan (200 mg per day); 4 on cortisone enema (1 - 2 times per day};
1 on lidocaine gel enema (2 times per day); and 1 on immodium (2 times per day).
The other seven subjects had reported being on a course of prednisone and/or
sulfasalazine at least once before their visit. Symptoms at presentation included:

16 with diarrhea (66. 7

%);

16 with bleeding (66. 7 %); 13 with pain or cramping

(54.2 %); 11 with mucous (45.8 %); 11 with stool frequency (45.8 %); 5 with bloating
(20.8 %); and 5 with gas (20.8 %). Subjects reportedly had their UC diagnosis from
2 months to 20 years (average 6. 2 years). They were followed in this study from 1 to
26 months (average 7.2 months). Monitoring of subject progress and data collection
ended July 31, 1995.
At the first visit after a complete medical work-up which included a history,
a physical examination and blood work, one of two staff medical doctors (RCA or
another physician) prescribed a specific nutritional regimen. Then the subject met with a
clinical nutritionist (JSE) who carefully explained the sugar-free, hypoallergenic diet. All
forms of sugar and foods which contained sugar were excluded from the diet. Allergenic
foods such as dairy products, peanuts, citrus, and yeast were excluded from all subject
diets. In addition, some patients had food sensitivity testing which suggested a further
restriction for wheat (7 subjects) and corn (3 subjects).
A subset of nine subjects had stool and rectal mucosa samples collected for
microbial and parasite analyses by Great Smokies Diagnostic Laboratories, Asheville,
NC. Parasite evaluations used enzyme immunoassays with monoclonal antibodies,
immunoflorescence assays with monoclonal antibodies and computer-enhanced video
microscopy. The presence of possible pathogens was assayed by culture techniques
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using standard media and incubation guidelines, and the Vitak system for colorimetric
identification of bacteria.
Nutritional supplementation varied from subject to subject based on practitioner(s)
seen, subject progress, supplement tolerance and compliance. Initially, every subject
took: (a) a multivitamin and mineral supplement; (b) an oil formula containing omega 3
and omega 6 fatty acids derived from fish oil, borage oil and flax oil (two subjects
instead took separate fish oil and borage oil supplements); and (c) a probiotic. For the
multivitamin and mineral supplement subjects took two to six tablets per day, receiving
nutrient amounts listed in Table 1. With regard to the oil supplement, subjects took
three to eight gelatin coated oil pills per day containing 400 mg fish oil, 400 mg of
borage oil and 400 mg of flax oil. Each pill therefore contained 152 mg oleic acid,
180 mg linoleic acid, 96 mg gamma linolenic acid, 164 mg alpha linolenic acid,
120 mg eicosapentenoic acid, 80 mg docosahexanoic acid, and 5 IU vitamin E. For the
probiotic, twelve subjects took a Bacillus laterosporus supplement (two to three capsules
per day - 280 mg each) and twelve subjects took a Lactobacillus formula containing
acidophilus, bifidus and bulgaris strains (two to eight capsules per day - approximately
500,000 spores each). In addition, 22 of 24 subjects took large doses of folate
(20 - 60 mg/day); 20 of 24 subjects took beta carotene (25,000 - 75,000 JU/day) and
18 of 24 subjects took vitamin A (20,000 - 40,000 IU/day). In addition, seven subjects
took calcium carbonate (500 - 1000 mg/day), and three subjects took extra zinc
(30 - 60 mg/day). Also, some subjects received supplements for specific symptoms
or disorders unrelated to UC and four subjects received intravenous nutrients. Finally,
it should be noted that glutamine was not a significant part of the regimen since
recognition of its effects is more recent and only three subjects took it toward the end
of their study participation.

Statistical Analysis
A sign test was used for evaluating clinical improvement in medicated and non-
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medicated subjects (19). Medication dose changes in subject subsets were assessed by
paired t-tests and by non-parametric Wilcoxon Ranked Sum tests.

RESULTS
Eighteen of twenty-four subjects (75%) with UC improved on a sugar-free
hypoallergenic diet with nutritional supplementation - see Table 2. This included twelve
of seventeen subjects on various UC medications at presentation who had symptomatic
improvement and/or medication reduction, and six of seven non-medicated subjects
who had symptomatic improvement. Using a simple sign test and a one-sided
alternative hypothesis against the null hypothesis that the procedures were equally
likely to help the subjects or not, the p value associated with twelve of seventeen
improvements is 0.015, a significant result. Additionally, it may be argued by a simple
statistical sign test that the treatment, which results in none of the seven non-medicated
subjects deteriorating, is significant (p = 0.016). Table 3 lists the specific symptom
changes for non-medicated subjects.
There was a trend toward reducing subject prednisone dose during the study
period while the sulfasalazine dose was significantly lower. The prednisone dose
decreased from 14.8 mg per day to 9.0 mg per day, see Figure 1. In spite of the
small sample size, this decrease in prednisone is very close to statistical significance.
A one-sided, paired t test results in a p value of 0.065. Similarly, the non-parametric
Wilcoxon Ranked Sum test yields a p value of 0. 066.
Sulfasalazine dose decreased from 2814 mg per day to 1375 mg per day, see
Figure 2. As measured by a number of statistical tests, this decrease in sulfasalazine
is significant. A one-sided, pooled t test yields a p value of 0.028. While a normal
probability plot shows no evidence of non-normality, we also used the non-parametric
Wilcoxon Ranked Sum to test the treatment effects on the sulfasalazine subjects.
This test has a p value of 0.0004, which is highly significant.
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The prednisone analysis did not include one subject who was considered an
outlier. He was not controlled on the protocol or a very high dose of prednisone, and
pursued further treatment elsewhere. The presentation dose was 2.5 mg per day and
the ending dose was 7 5 mg per day (more medication than the ending dose of the

other six prednisone subjects combined).
Five subjects were able to stop their medication during the study period. This
included two subjects who had to restart medication again, although their symptoms
were able to be controlled at lower doses than at their initial presentation. The three
remaining patients were still off medication at the end of the study period.
Table 4 presents the results of a subset of subjects with microflora analyses.
As indicated, 2/9 had a parasite and 3/9 had possible pathogens. In addition, 6/9 had
imbalanced flora as indicated by inadequate amounts of lactobacillus species and/or
E. coli (5/9), and excessive amounts of Enterobacter cloacae, Hemolytic E. coli and/or
Morganella morganii (2/9).

DISCUSSION
The results of this retrospective chart-review study suggest that a dietary and
nutritional supplementation regimen can significantly benefit UC patients. This study
finding is based on significant improvements in medication dose and symptoms. We
also suggest that UC is a multifactorial disorder. As such, a comprehensive therapeutic
nutritional program will more likely help UC patients more, and produce more consistant
study results, than a single dietary factor or nutritional supplement will. Future research
is necessary, however, to confirm these results, and to clarify the relationship between
nutritional factors and UC.
These findings are reported with the understanding that chart review research has
many weaknesses and this study is no exception. Weaknesses included (a) inconsistent
nutritional regimes; (b) variations in subject study periods; (c) self-reporting of
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symptoms; (d) the potential for observational bias; (e) possible sample selection bias;
(f) the inability to draw conclusions as to the relative importance of the specific dietary
guidelines followed and nutritional supplements taken; and (g) the inability to assess ·
specific mechanisms involved. While the self-reporting of symptoms is open for bias
and this was compounded by the sometimes inconsistent listing of subject symptoms
at follow-up appointments, subjects were reporting on changes in more than three
symptoms. Therefore, they would be more likely to have given accurate responses for
overall improvement or non-improvement.
With regard to sample selection bias, this resulted from the eleven potential
subjects who were excluded from the study due to inadequate follow-up (nine) or
non-compliance (two). The often severe dietary restrictions and large requirement for
supplement ingestion could have selected more highly motivated subjects. Therefore,
the results may not be generalizable to all subjects with UC.
In research on diets followed prior to acute exacerbations of UC it was shown
that individuals eating higher levels of sugar (3) and fast food (7) were at greater
risk. Investigations of food sensitivity or allergy showed elevated levels of cow's milk
antibodies in UC patients in one study (5) and 70 % of subjects in another study reported
concomitant symptoms which were judged to be possibly allergic (6). Also, a clinical trial
of a dairy-free diet showed a decreased relapse rate and this effect was more pronounced
in patients with a history· of UC less than three years (1). However, other findings have
not confirmed pre-illness diet or allergenic effects in relation to UC development or
treatment (4,20-23), and no recent studies have examined therapeutic influences of diet.
In contrast, however, dietary studies of Crohn's disease have consistently found
increased levels of sugar intake (4,24,25). As a result, more studies of Crohn's disease
have explored therapeutic dietary effects. One study found that a sugar-free diet
significantly reduced relapse rates (26), whereas another did not (27). A third investigation found that it was the hypoallergenic or exclusion diet that produced the benefits for
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ongoing patients and not the sugar-free diet (28). More consistent dietary effects may be
observed in Crohn's disease in comparison to UC because dietary sugars and antigenic
proteins may more likely reach involved intestinal mucosa and gut-associated lymphatic
tissues that may influence mechanisms of disease activity.
The investigations of nutritional therapy as primary treatment for UC have
examined in hospitalized patients the extent to which total parenteral nutrition (TPN)

and bowel rest might influence remission rates (29,30). One study found that the
severity of inflammation and the amount of colonic involvement affected whether the
nutritional therapy was helpful (29). These two factors may be important determinants
in evaluating success of nutritional factors and therapies, and may help explain
nutritional research inconsistencies.
Symptoms of UC such as malabsorption and blood loss, as well as nutrient-drug
interactions, suggest that nutritional deficiency might be common and have a role in
UC pathology, yet studies have not generally found this. Folate deficiency was observed
in one large study of chronic inflammatory bowel disease patients (10), with anti-folate· effects of sulfasalazine having a significant effect (31). In addition, a study of colorectal
cancer and inflammatory bowel disease showed a significantly lower level of serum
retinal in UC patients versus controls (32). Other studies suggest that UC patients may
have subclinical or clinical deficiency of zinc, magnesium, calcium and/or iron, especially
with greater severity of disease (33-36). Finally, research on UC mucosa samples have
shown altered ascorbic acid status (37) and decreased antioxidant defenses (38).
With regard to nutritional supplementation research, probably the most significant
investigation examined the influence of fish oil on UC and observed anti-inflammatory
effects that may have derived from decreased Ieukotriene B4 levels (2). This result was
accompanied by improved histology indices and significant weight gain. A subgroup on
prednisone also showed a non-significant average decrease from 12.9 mg per day to 6.1
mg per day. Only modest clinical improvements were noted, however, so researchers
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concluded that fish oil could not be recommended as a simple treatment for UC.
A case report of UC showed beneficial results from supplementation with
alpha-tocopherolquinone and the effects were thought to have resulted from bowel flora
influences (12). A direct study of microflora changes in active UC found significantly
reduced counts of total flora, obligate anaerobes (eg. bifidobacteria}, facultative
organisms, and microaerobes (eg. lactobacilli) (13). In addition, more general probiotic
'nutritional supplementation' research has shown that: (a) supplementing with freeze
dried Lactobacillus GG reduced the susceptibility of subjects to traveller's diarrhea (39);
(b) Lactobacillus GG yogurt reduced antibiotic associated diarrhea (40); (c) a milk
concentrate of Lactobacillus GG effectively treated relapsing Clostridium difficile colitis
(16); and (d) Lactobacillus GG significantly benefitted pouchitis, a complication of ilea!
reservoir surgery in UC patients who have had a proctocolectomy (17).
There was a subset of subjects in this study in which bowel flora assessments
were made. However, it was too small a sample to determine if this had an effect and

there were no follow-up tests done to evaluate flora changes or its influence on clinical·
parameters. In addition, there is considerable controversy regarding what constitutes
normal and imbalanced flora, the degree to which it may be altered by various means,
whether it is altered in UC and the impact which flora has on UC and health (13,41-43).
Another potentially important aspect of bowel flora influence was shown in a
clinical study of 25 UC patients in which it was determined that 88 % had systemic
endotoxemia, and this positively correlated with anatomic extent of disease and disease
activity (15). Other studies have also found endotoxemia in

ue and its correlation with

disease activity (44,45). The amino acid glutamine may be benefitial for UC because in
addition to its important role as an energy source for dividing cells in the small intestine
and to a lesser extent colonocytes (46), an animal model of UC found that glutamine
supplementation was shown to significantly decrease portal vein endotoxin levels (9).
A final mechanism by which bowel flora may influence UC is via immune
function. This was suggested by a report that found that mesenteric lymph node
9

mononuclear cells showed significantly greater responses to flora antigens (cell-mediated
immunological measure) than did peripheral blood mononuclear cells (4 7). While the
implications are unknown, this suggests that a localized immunological reactivity to flora
antigens does occur. Also, this raises questions regarding a potential exacerbating effect
based on constituant flora and whether another factor, food antigen influences or food
··allergies/sensitivities, may need to be assessed by more localized tests such as mesenteric

lymph node mononuclear cell reactivity.
Other intestinal immune function studies have shown that nutritional supplementation may have a significant affect as well (48,50}. For example, one investigation of
glutamine-supplemented TPN found a significant increase in biliary secretory lgA (48)
and another showed that oral glutamine had more beneficial effects than intravenous
glutamine (49). The latter finding suggests a localized effect which would be derived
from oral nutritional supplementation.
A similar localized effect may also be found for folate since one researcher has
suggested a possible mucosa! deficiency of this vitamin in UC (51}. It is well established ·
that folate is involved in methyltransfer reactions in the synthesis of DNA. Studies have
shown that 10,000 micrograms per day will significantly increase methylation pathways
(52), and that folate supplementation may decrease the risk for dysplasias that are more
common in UC (11}. Folate therefore may affect UC is via cellular development and
turnover, and this was the rationale for the high dose of folate given in this study, as well
as the high doses of vitamin A and beta carotene.
What emerges from a discussion of these various areas of investigation is that
UC is a multifactorial disease that requires examination by a more comprehensive model
- see Figure 3. This model shows that dietary guidelines and nutritional supplementation
may influence two primary categories. These are: (a) bowel flora composition, and
related factors such as .endotoxin secretion and colonization resistance; and more
importantly (b} intestinal parameters at the cellular and tissue level as well as
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immunological measures which are integrated into both. This latter category includes a
wide range of histologic measures and sigmoidoscopy indices as well as eicosanoid
production, intestinal permeability, immune reactivity and others. These categories may
then influence systemic factors such as endotoxemia and liver detoxification, and all of
these factors combine to produce UC symptoms.
Further research is clearly indicated to answer many of the questions about

the relationship between nutritional factors and UC. The investigations should be:
(a) prospective; (b) larger in sample size and use a control group; (c) standard in
nutritional regimen and study length; (d) include objective measures of UC activity such
as sigmoidoscopy scores, histology indices, disease activity indices and relapse rates; and
(e) use appropriate study designs that examine multifactorial disorders. In addition, it
may be necessary to examine individual nutritional factors and their effect on some of
the intermediary measures that have been discussed. These types of studies may show
influences of these factors on UC measures but they may not be large enough to affect
clinical symptoms. This may however allow for the identification of more subtle relation-·
ships, and there may be several.
Additionally, if a multifactorial model was determined to be more accurate,
there may be subsets of UC patients who may be affected more by some intermediary
factors rather than others. The most effective nutritional regimen may then need to be
uniquely developed for each UC patient from reliable measures assessed. It also may
be necessary to enlarge the model beyond nutrition to add factors such as stress and
modalities such as acupuncture.
Finally, it is astonishing that there has been little or no progress made in the
understanding of nutritional influences on UC over the last thirty to forty years. While
the specific relationships remain to be identified, this can only be scientifically done
through well designed future research.
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Table 1. Multivitamin and Mineral Composition*
Nutrient
Vitamin A
Beta Carotene
Vitamin D2
Thiamine
Riboflavin
Niacin
Niacinamide
Pantethine
Pantothenic Acid
Pyridoxine
.
Pyridoxal 5 Phosphate
Cyanocobalamin
Folate
Biotin
Choline
Inositol
PABA
Ascorbate
Citrus Bioflavinoids
Alpha Tocopherol
Copper
Magnesium
Manganese
Chromium
Molybdenum
Vanadium
Selenium
Octacosanol
N Acetyl Cysteine
Reduced Glutathione

Per Tablet

Total

200IU
500IU
15IU

400-1200 IU
1000-3000 IU
30-90 IU
10-30 mg
8-24 mg
4-12 mg
10-30 mg
50-150 mg
50-150 mg
40-120 mg

5mg

4mg

2mg
5mg

25 mg
25mg
20 mg
2mg
30 ug
100 ug
75 ug
100 mg
80 mg
100 mg
120 mg
150 mg
20IU
200 ug

4-12mg

60-180ug
200-600 ug
150-450 ug
200-600 mg
160-480 mg
200-600 mg
240-720 mg
300-900 mg
40-120 IU
400-1200 ug
16-48 mg
8-24 mg
100-300 ug
20-60 ug
30-90 ug
80-240 ug
300-900 ug
40-120 ug
10-30 mg

8mg
4mg

50 ug
10 ug
15ug
40 ug
150 ug
20 ug
5mg

* Subjects took 2-6 tablets per day.
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RESULTS
Table 2. Nutritional Regimen Effects
Medication
Status at
Presentation

;

Not Improved
Same Worse

Number of
Subjects

Improved

On medication*

17

12

2

3

Off medication

7

6

1

0

24

18

3

3

TOTALS

* 5/17 subjects {29.4%) were able to stop medication altogether, although
only 3/17 subjects {17 .6%) were able to stay off the medication for the
entire study period.

Table 3. Specific Symptom Changes for Subjects NOT on
Medication at Presentation (N= 7)*
Not Improved
Same Worse

Number of
Subjects·

Improved

Diarrhea

6

6

0

0

Bleeding

5

4

1

0

Mucous

3

2

1

0

Pain or Cramps

3

3

0

0

Bloating

1

1

0

0

Gas

3

3

0

0

Stool Frequency

3

3

0

0

Symptoms

*Subjects reported an average of 3.3 symptoms.
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Table 4. Microbial Analysis in Sample Subset (n=9)
Subject
Number

Parasite

Possible PathQgen

Imbalanced Flora
Excess

2

Chilornastix
mesnili

5

6

Inadeguate

Enterobacter
cloacae
Citrobacter
freundi
Klebsiella
pneumonia

Blastocystis
hominis

Citrobacter
freundi
Klebsiella.
pneumonia
Proteus vulgaris

10

LactobaciUus

11

Lactobacillus

13

Lactobacillus
E. coli

15

Lactobacillus

17

18

Hemolytic E.coli
Morganella
Morganii
Klebsiella
pneumonia

18

E.coli
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Prednisone
Dose

14.8

15

(mg)
9.0

10
5

Beginning

Ending

Figure 1. Change in Subject Prednisone Dose with Nutritional
Regimen* (N=6, P=0.065)
*One outlier was excluded from the calculation.

3000

2814

Sulfasalazine
Dose
2000
(mg)

1315

1000

Beginning

Ending

Figure 2. Change in Subject Sulfasalazine Dose with Nutritional
Regimen (N=8, P=0.028)
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Nutritional Supplements:

Dietary Factors:

•
•
•
•
•

• Sugars
• Food antigens
• Others

Omega 3 and 6 Fatty Acids
Probiotics
Glutamine
Folate
Others

Bowel Flora Composition:

Intestinal Effects:

-----------------------------,----------------------------Cellular

: Mucosal Tissue

• Histology measures:
Loss of polarity
Mucin content of surface
epithelium
Denudation or erosion
Superficial and deep
inflammatory cell
infiltrate
Architectural distortion
Fibrosis
• Impaired antioxidant
defenses

• Inflammation and
ulceration
• Anatomic extent of
disease
• Intestinal permeability
• Sigmoidoscopy measures:
:
Granularity
I
:
Friability
:
Mucopus
:I
:
:

•
•
•
•

Species types and amount
Toxin secretion
Colonization resistance
Bacterial Fermentation synthesis of short chain
fatty acids

• pH
• Rule out parasites

I

r---------------------~-----------------------,
I
I
I

Immunologic

• Secretory IgA
• Mesenteric lymph node
mononuclear cell reactivity
• Eicosanoid production
• Other GALT functions

Systemic Effects:

• Endotoxemia, acute phase
proteins, circulating TNF
• Liver detoxification

Ulcerative Colitis Symptoms:
•
•
•
•

Bleeding
Diarrhea
Bloating
Pain and cramps

• Mucous
• Stool frequency
• Gas

Figure 3. Multifactorial model of nutritional therapy in Ulcerative Colitis.
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